Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03862040 · ClinicalTrials.gov registry record · Phase 1
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
A Phase 1 study, sponsored by Shionogi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03862040 is a Phase 1 study that was terminated before completion, run by Shionogi. The registered enrollment target is 7 participants.
The verdict
NCT03862040, a Phase 1 study, was terminated before completion, sponsored by Shionogi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary purpose of the study is to determine the degree of penetration of cefiderocol into infected lung tissue in hospitalized adults with bacterial pneumonia who are being mechanically ventilated.
Interventions
- DRUG Cefiderocol
- DRUG Standard of Care Antibiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03862040
The ClinicalTrials.gov registry entry for NCT03862040 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefiderocol is the first listed.
NCT03862040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03862040 about?
NCT03862040 is a clinical study titled "Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia". The primary purpose of the study is to determine the degree of penetration of cefiderocol into infected lung tissue in hospitalized adults with bacterial pneumonia who are being mechanically ventilated.
What is the current status of trial NCT03862040?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-02-20. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT03862040?
The interventions under investigation include: Cefiderocol (DRUG), Standard of Care Antibiotic (DRUG).
Who is sponsoring clinical trial NCT03862040?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.